DCPH Deciphera Pharmaceuticals
- 25.500
- +0.020+0.08%
- 25.550
- +0.050+0.20%
Deciphera Pharmaceuticals News
Deciphera Pharmaceuticals Ticks Higher as HSR Waiting Period for ONO Sale Expires
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
Deciphera Pharmaceuticals: Hold Rating Amid Acquisition and Concerns Over Qinlock Sales
Deciphera Pharmaceuticals: A Hold Rating Amidst Ono Pharmaceutical Acquisition Offer
Deciphera Pharmaceuticals (DCPH.US): The 2024 Q1 financial report achieved revenue of US$44.99 million, with a previous value of US$334.45 million and an expected value of US$46.28 million; earnings per share was -0.52 US dollars, the previous value was -
Deciphera Pharmaceuticals (DCPH.US): The 2024 Q1 financial report achieved revenue of US$44.99 million, with a previous value of US$334.45 million and an expected value of US$46.28 million; earnings per share was -0.52 US dollars, the previous value was -0.60 US dollars, and the expected value was -0.55 US dollars.
Deciphera Pharmaceuticals | 10-Q: Quarterly report
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Butterfly Network (BFLY) and Deciphera Pharmaceuticals (DCPH)
Catalyst Watch: Disney Earnings, Apple iPad Event and Fed Speakers Back on the Circuit
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Deciphera Pharmaceuticals Cut to Neutral From Buy by Guggenheim
Deciphera Pharmaceuticals Cut to Neutral From Buy by Guggenheim
Guggenheim Downgrades Deciphera Pharmaceuticals to Neutral
Guggenheim analyst Michael Schmidt downgrades Deciphera Pharmaceuticals from Buy to Neutral.
Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
In the last three months, 5 analysts have published ratings on Deciphera Pharmaceuticals (NASDAQ:DCPH), offering a diverse range of perspectives from bullish to bearish.The table below summarizes thei
Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target Is $26
Deciphera Pharmaceuticals (DCPH) has an average outperform rating and a price target range of $23 to $30, according to analysts polled by Capital IQ. Price: 25.17, Change: -0.11, Percent Change: -0.44
JMP Downgrades Deciphera Pharmaceuticals to Market Perform
Deciphera Pharmaceuticals (DCPH) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $23 to $30. Price: 25.21, Change: -0.07, Percent Ch
ONO Enters Into A Definitive Agreement To Acquire Deciphera Pharmaceuticals >4528.TO
ONO Enters Into A Definitive Agreement To Acquire Deciphera Pharmaceuticals >4528.TO
Japan's Ono Pharma Says $2.4 Bln Deciphera Purchase 'First Step' for Global Expansion
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week
US equity markets ended higher Monday as investors awaited key corporate earnings, including Apple (AAPL), Amazon.com (AMZN) and Eli Lilly (LLY), and the Federal Reserve's policy meeting this week. *
Janux Therapeutics Jumps as Much as 28% on Heels of Deciphera Buyout Deal
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Deciphera Pharmaceuticals, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - April 29, 2024) - Rigrodsky Law, P.A. is investigating Deciphera Pharmaceuticals, Inc. ("Deciphera") (NASDAQ: DCPH) regarding possible breaches of fiduciary dut
Deciphera Pharmaceuticals (DCPH) Was Downgraded to a Hold Rating at JMP Securities
Analysis
Price Target
No Data
